Dissociated response as a new biomarker of treatment response in neuroendocrine tumors: Results from phase 3 of the RAISE project

#3234

Introduction: RAISE aimed to find a surrogate endpoint to early predict treatment efficacy in patients with neuroendocrine tumors (NET). Dissociated response is the inhomogeneous response of the different lesions of a patient. Its prognostic value remains unclear.

Aim(s): To investigate the value of dissociated response as an early biomarker of treatment response in patients with NET.

Materials and methods: Dissociated response was estimated by the standard deviation of longest diameter ratio of lesions in patients with multiple lesions (n=148/204) in CLARINET: A placebo-controlled study assessing lanreotide in tumor control of gastroenteropancreatic NET. Cox regression analyses evaluated association of dissociated response with NET progression and whether it improved early progression-free survival (PFS) prediction when combined with sum of the longest diameter ratio (SLDr) and change in log chromogranin A (CgA). Proportion explained quantified model surrogacy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Dromain C

Authors: Dromain C, Pavel M, Ronot M, Schaefer N, Mandair D,

Keywords: neuroendocrine tumor, dissociated response, progression-free survival, prediction,